IntelGenx Technologies (IGXT) has released an update.
IntelGenx Corp., a drug delivery company, has initiated a Sale and Investment Solicitation Process (SISP) after receiving court-ordered protection. With assistance from Ernst & Young entities, the company aims to secure superior bids over the established ‘stalking horse’ bid from atai Life Sciences AG. Interested parties have until July 15, 2024, to submit their bids for the company’s assets or business.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.
